title: The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients.
abstract: Approximately, up to 70 % of the human population is infected with cytomegalovirus (CMV) that persists for life in a latent state. In healthy people, CMV reactivation induces the expansion of CMV-specific T cells up to 10 % of the entire T cell repertoire. On the contrary, CMV infection is a major opportunistic viral pathogen that remains a leading cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. Due to the delayed CMV-specific immune recovery, the incidence of CMV reactivation during post-transplant period is very high. Several methods are currently available for the monitoring of CMV-specific responses that help in clinical monitoring. In this review, essential aspects in the immune recovery against CMV are discussed to improve the better understanding of the immune system relying on CMV infection and, thereby, helping the avoidance of CMV disease or reactivation following hematopoietic stem cell transplantation with severe consequences for the transplanted patients.
authors.affiliation: Oncohematology Research Group, Navarrabiomed-Fundación Miguel Servet, IDISNA (Navarra's Health Research Institute), Irunlarrea 3 Street, 31008, Pamplona, Navarra, Spain.
authors.forename: Miriam
authors.initials: M
authors.lastname: Ciáurriz
authors.affiliation: Oncohematology Research Group, Navarrabiomed-Fundación Miguel Servet, IDISNA (Navarra's Health Research Institute), Irunlarrea 3 Street, 31008, Pamplona, Navarra, Spain.|Hematology Department, Complejo Hospitalario de Navarra, Navarra Health Service, IDISNA, Pamplona, Navarra, Spain.
authors.forename: Amaya
authors.initials: A
authors.lastname: Zabalza
authors.affiliation: Oncohematology Research Group, Navarrabiomed-Fundación Miguel Servet, IDISNA (Navarra's Health Research Institute), Irunlarrea 3 Street, 31008, Pamplona, Navarra, Spain.
authors.forename: Lorea
authors.initials: L
authors.lastname: Beloki
authors.affiliation: Oncohematology Research Group, Navarrabiomed-Fundación Miguel Servet, IDISNA (Navarra's Health Research Institute), Irunlarrea 3 Street, 31008, Pamplona, Navarra, Spain.
authors.forename: Cristina
authors.initials: C
authors.lastname: Mansilla
authors.affiliation: Oncohematology Research Group, Navarrabiomed-Fundación Miguel Servet, IDISNA (Navarra's Health Research Institute), Irunlarrea 3 Street, 31008, Pamplona, Navarra, Spain.
authors.forename: Estela
authors.initials: E
authors.lastname: Pérez-Valderrama
authors.affiliation: Oncohematology Research Group, Navarrabiomed-Fundación Miguel Servet, IDISNA (Navarra's Health Research Institute), Irunlarrea 3 Street, 31008, Pamplona, Navarra, Spain.
authors.forename: Mercedes
authors.initials: M
authors.lastname: Lachén
authors.affiliation: Oncohematology Research Group, Navarrabiomed-Fundación Miguel Servet, IDISNA (Navarra's Health Research Institute), Irunlarrea 3 Street, 31008, Pamplona, Navarra, Spain.|Hematology Department, Complejo Hospitalario de Navarra, Navarra Health Service, IDISNA, Pamplona, Navarra, Spain.|Immunity Unit, Complejo Hospitalario de Navarra, Navarra Health Service, IDISNA, Pamplona, Navarra, Spain.
authors.forename: Eva
authors.initials: E
authors.lastname: Bandrés
authors.affiliation: Oncohematology Research Group, Navarrabiomed-Fundación Miguel Servet, IDISNA (Navarra's Health Research Institute), Irunlarrea 3 Street, 31008, Pamplona, Navarra, Spain.|Hammersmith Hospital-Imperial College Healthcare NHS, London, UK.
authors.forename: Eduardo
authors.initials: E
authors.lastname: Olavarría
authors.affiliation: Oncohematology Research Group, Navarrabiomed-Fundación Miguel Servet, IDISNA (Navarra's Health Research Institute), Irunlarrea 3 Street, 31008, Pamplona, Navarra, Spain. nramireh@cfnavarra.es.
authors.forename: Natalia
authors.initials: N
authors.lastname: Ramírez
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology; D018414:CD8-Positive T-Lymphocytes / Q000821:virology; D016207:Cytokines / Q000378:metabolism; D003587:Cytomegalovirus / Q000472:pathogenicity* / Q000502:physiology; D003586:Cytomegalovirus Infections / Q000276:immunology* / Q000517:prevention & control / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016867:Immunocompromised Host / Q000276:immunology; D016219:Immunotherapy, Adoptive / Q000379:methods; D007694:Killer Cells, Natural / Q000276:immunology; D011110:Polymorphism, Genetic; D019713:Receptors, CCR5 / Q000235:genetics / Q000276:immunology; D014019:Tissue Donors; D019172:Transplantation Conditioning / Q000379:methods; D014184:Transplantation, Homologous; D014775:Virus Activation
chemical_list: D000998:Antiviral Agents; C584933:CCR5 protein, human; D016207:Cytokines; D019713:Receptors, CCR5
keywords: Allogeneic HSCT; CMV-specific T cells; Immune monitoring